Advancing Paediatric Drug Development Through Optimised Study Design
We are pleased to highlight a new scientific publication by Phanio Djokoto, now available on Springer Nature Link, which contributes to advancing methodologies in paediatric drug development.
Designing clinical studies in children presents a unique and complex challenge. Ethical considerations require minimising the burden placed on young patients, while scientific rigor demands that collected data remain robust, reliable, and sufficient to support regulatory decision-making. In this context, extrapolation-based drug development has emerged as a powerful approach, enabling researchers to leverage existing knowledge—often from adult populations—to inform paediatric studies and reduce the need for extensive clinical trials.
This newly published work focuses on optimising paediatric pharmacokinetic (PK) study design within this framework. Specifically, it introduces a stochastic simulation–estimation (SSE) approach to support the prospective evaluation and refinement of study designs before they are implemented in real-world settings.
The proposed SSE framework allows researchers to systematically explore and optimise key design parameters, including:
The number of patients enrolled in a study
The frequency of pharmacokinetic sampling
The timing of sample collection
By simulating a wide range of scenarios and evaluating their statistical performance, the approach enables the identification of study designs that strike the right balance between precision, bias, and feasibility.
The findings demonstrate that SSE can reliably identify designs that achieve acceptable levels of accuracy while minimising unnecessary data collection. This makes it a practical and quantitative decision-support tool not only for drug developers, but also for regulatory authorities assessing the adequacy of proposed study designs.
Beyond its technical contribution, this work addresses a broader and critical objective: improving both the ethical and scientific standards of paediatric research. By ensuring that studies are designed to collect only the most essential data—while maximising the information gained—this approach helps reduce patient burden and enhances the overall efficiency of drug development.
Ultimately, this research reinforces the importance of innovative methodologies in shaping a more responsible, data-driven future for paediatric medicine.
Read the full article here.
